Disclosed is a pharmaceutical preparation comprising two daily doses of about 6.6 grams per day of balsalazide or a pharmaceutically acceptable salt, solvate, or clathrate thereof made by the process, comprising: granulating a balsalazide disodiumfeed powder and one or more excipients to form granules； sizing the granules； blending the granules for about 20 minutes to form a powder blend； and encapsulating the powder blend, wherein the encapsulated powder blend may optionally be polished after encapsulation.
